COLUMBUS-AD: Phase III Study of Adjuvant Encorafenib + Binimetinib in Resected Stage IIB/IIC BRAF V600-Mutated Melanoma

References

• Matthews NH , LiW-Q, QureshiAA, WeinstockMA, ChoE. Epidemiology of melanoma. In: Cutaneous melanoma: etiology and therapy.WardWH, FarmaJM. ( Eds). Codon Publications, Brisbane, Australia (2017).
   Google Scholar
• International Agency for Research on Cancer . Cancer over time (2021). https://gco.iarc.fr/overtime (Accessed 23December2021).
   Google Scholar
• Poklepovic AS , LukeJJ. Considering adjuvant therapy for stage II melanoma. Cancer126(6), 1166–1174 (2020).
   PubMed Web of Science ®Google Scholar
• Miller R , WalkerS, ShuiI, BrandtmullerA, CadwellK, ScherrerE. Epidemiology and survival outcomes in stages II and III cutaneous melanoma: a systematic review. Melanoma Manag.7(1), MMT39 (2020).
   PubMed Web of Science ®Google Scholar
• Greaves WO , VermaS, PatelKPet al. Frequency and spectrum of BRAF mutations in a retrospective, single-institution study of 1112 cases of melanoma. J Mol Diagn.15(2), 220–226 (2013).
   PubMed Web of Science ®Google Scholar
• Cheng L , Lopez-BeltranA, MassariF, MacLennanGT, MontironiR. Molecular testing for BRAF mutations to inform melanoma treatment decisions: a move toward precision medicine. Mod. Pathol.31(1), 24–38 (2018).
   PubMed Web of Science ®Google Scholar
• Long GV , MenziesAM, NagrialAMet al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J. Clin. Oncol.29(10), 1239–1246 (2011).
   PubMed Web of Science ®Google Scholar
• Wolfe AR , ChablaniP, SiedowMRet al. BRAF mutation correlates with worse local-regional control following radiation therapy in patients with stage III melanoma. Radiat Oncol.16(1), 181 (2021).
   PubMed Web of Science ®Google Scholar
• Corrie PG , MarshallA, NathanPDet al. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Ann. Oncol.29(8), 1843–1852 (2018).
   PubMed Web of Science ®Google Scholar
• Gershenwald JE , ScolyerRA. Melanoma staging: American Joint Committee on Cancer (AJCC) 8th edition and beyond. Ann. Surg. Oncol.25(8), 2105–2110 (2018).
   PubMed Web of Science ®Google Scholar
• Lee AY , DroppelmannN, PanageasKSet al. Patterns and timing of initial relapse in pathologic stage II melanoma patients. Ann. Surg. Oncol.24(4), 939–946 (2017).
   PubMed Web of Science ®Google Scholar
• Long GV , LukeJJ, KhattakMAet al. Pembrolizumab versus placebo as adjuvant therapy in resected stage IIB or IIC melanoma (KEYNOTE-716): distant metastasis-free survival results of a multicentre, double-blind, randomised, Phase III trial. Lancet Oncol.23(11), 1378–1388 (2022).
   PubMed Web of Science ®Google Scholar
• Bleicher J , SwordsDS, MaliMEet al. Recurrence patterns in patients with stage II melanoma: the evolving role of routine imaging for surveillance. J. Surg. Oncol.122(8), 1770–1777 (2020).
   PubMed Web of Science ®Google Scholar
• Eggermont AMM , RutkowskiP, DutriauxCet al. Adjuvant therapy with pegylated interferon-alfa2b vs observation in stage II B/C patients with ulcerated primary: results of the European Organisation for research and treatment of cancer 18081 randomised trial. Eur. J. Cancer133, 94–103 (2020).
   PubMed Web of Science ®Google Scholar
• Gillgren P , DrzewieckiKT, NiinMet al. 2-cm versus 4-cm surgical excision margins for primary cutaneous melanoma thicker than 2 mm: a randomised, multicentre trial. Lancet378(9803), 1635–1642 (2011).
   PubMed Web of Science ®Google Scholar
• Garbe C , KeimU, AmaralTet al. Prognosis of patients with primary melanoma stage I and II according to American Joint Committee on Cancer version 8 validated in two independent cohorts: implications for adjuvant treatment. J. Clin. Oncol.40(32), 3741–3749 (2022).
   PubMed Web of Science ®Google Scholar
• Perez MC , TanabeKK, AriyanCEet al. Local and recurrent regional metastases of melanoma. In: Cutaneous Melanoma.BalchCM, AtkinsMB, GarbeCet al. et al. ( Eds). 705–737 (2019).
   Google Scholar
• Trojaniello C , LukeJJ, AsciertoPA. Therapeutic advancements across clinical stages in melanoma, with a focus on targeted immunotherapy. Front Oncol.11, 670726 (2021).
   PubMed Web of Science ®Google Scholar
• Michielin O , van AkkooiACJ, AsciertoPA, DummerR, KeilholzU. ESMO Guidelines Committee. Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol.30(12), 1884–1901 (2019).
   PubMed Web of Science ®Google Scholar
• Coit DG , ThompsonJA, AlbertiniMRet al. Cutaneous melanoma, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw.17(4), 367–402 (2019).
   PubMed Web of Science ®Google Scholar
• Long G . Adjuvant therapy with nivolumab versus placebo in patients with stage IIB/C melanoma (CheckMate 76K) [late-breaking plenary abstract]. Presented at: Society of Melanoma Research (SMR) International Congress. (19 October 2022).
   Google Scholar
• Dummer R , AsciertoPA, GogasHJet al. Overall survival in patients with BRAF-mutant melanoma receiving encorafenib plus binimetinib versus vemurafenib or encorafenib (COLUMBUS): a multicentre, open-label, randomised, Phase III trial. Lancet Oncol.19(10), 1315–1327 (2018).
   PubMed Web of Science ®Google Scholar
• Dummer R , AsciertoPA, GogasHJet al. Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised Phase III trial. Lancet Oncol.19(5), 603–615 (2018).
   PubMed Web of Science ®Google Scholar
• Larkin J , AsciertoPA, DrenoBet al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N. Engl. J. Med.371(20), 1867–1876 (2014).
   PubMed Web of Science ®Google Scholar
• Long GV , StroyakovskiyD, GogasHet al. Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, Phase III randomised controlled trial. Lancet386(9992), 444–451 (2015).
   PubMed Web of Science ®Google Scholar
• Dummer R , HauschildA, SantinamiMet al. Five-year analysis of adjuvant dabrafenib plus trametinib in stage III melanoma. N. Engl. J. Med.383(12), 1139–1148 (2020).
   PubMed Web of Science ®Google Scholar
• Long GV , HauschildA, SantinamiMet al. Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma. N. Engl. J. Med.377(19), 1813–1823 (2017).
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration . FDA approves pembrolizumab for adjuvant treatment of Stage IIB or IIC melanoma (2021). www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-adjuvant-treatment-stage-iib-or-iic-melanoma (Accessed 3December2021).
   Google Scholar
• European Medicines Agency . KEYTRUDA (pembrolizumab) 25mg/mL concentrate for solution for infusion: summary of product characteristics (2022). www.ema.europa.eu/documents/product-information/keytruda-epar-product-information_en.pdf (Accessed 28July2022).
   Google Scholar
• Ghisoni E , WickyA, BouchaabHet al. Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: an overlooked aspect in immunotherapy. Eur. J. Cancer149, 153–164 (2021).
   PubMed Web of Science ®Google Scholar
• de Meza MM , IsmailRK, RauwerdinkDet al. Adjuvant treatment for melanoma in clinical practice - Trial versus reality. Eur. J. Cancer158, 234–245 (2021).
   PubMed Web of Science ®Google Scholar
• Johnson DB , NebhanCA, MoslehiJJ, BalkoJM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol.19(4), 254–267 (2022).
   PubMed Web of Science ®Google Scholar
• Dimitriou F , LongGV, MenziesAM. Novel adjuvant options for cutaneous melanoma. Ann. Oncol.32(7), 854–865 (2021).
   PubMed Web of Science ®Google Scholar
• Funck-Brentano E , MalissenN, RogerAet al. Which adjuvant treatment for patients with BRAF(V600)-mutant cutaneous melanoma? Ann Dermatol Venereol. 148(3), 145–155 (2021).
   PubMed Web of Science ®Google Scholar
• Heinzerling L , EigentlerTK, FluckMet al. Tolerability of BRAF/MEK inhibitor combinations: adverse event evaluation and management. ESMO Open.4(3), e000491 (2019).
   PubMed Web of Science ®Google Scholar
• Laupacis A , SackettDL, RobertsRS. An assessment of clinically useful measures of the consequences of treatment. N. Engl. J. Med.318(26), 1728–1733 (1988).
   PubMed Web of Science ®Google Scholar
• Rohatgi A , KirkwoodJM. Beyond PD-1: the next frontier for immunotherapy in melanoma. Front Oncol.11, 640314 (2021).
   PubMed Web of Science ®Google Scholar
• Binimetinib plus encorafenib for metastatic melanoma. Aust Prescr.42(5), 168 (2019).
   PubMed Web of Science ®Google Scholar
• US Food and Drug Administration . BRAFTOVI™ (encorafenib) capsules, for oral use: highlights of prescribing information (2018). www.accessdata.fda.gov/drugsatfda_docs/label/2018/210496lbl.pdf (Accessed 15June2022).
   Google Scholar
• US Food and Drug Administration . MEKTOVI® (binimetinib) tablets, for oral use: highlights of prescribing information (2018). www.accessdata.fda.gov/drugsatfda_docs/label/2018/210498lbl.pdf (Accessed 15June2022).
   Google Scholar
• European Medicines Agency . Braftovi (encorafenib) 50 mg/75 mg hard capsules: summary of product characteristics (2018). www.ema.europa.eu/en/documents/product-information/braftovi-epar-product-information_en.pdf (Accessed 6December2022).
   Google Scholar
• European Medicines Agency . Mektovi (binimetinib) 15 mg film-coated tablets: summary of product characteristics (2018). www.ema.europa.eu/en/documents/product-information/mektovi-epar-product-information_en.pdf (Accessed 6December2022).
   Google Scholar
• National Comprehensive Cancer Network . NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®). Melanoma: cutaneous, version 2.2023 — March 10, 2023. (2023). www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf (Accessed June 9 2023).
   Google Scholar
• Gershenwald JE , ScolyerRA, HessKRet al. Melanoma staging: evidence-based changes in the American Joint Committee on Cancer eighth edition cancer staging manual. CA Cancer J. Clin.67(6), 472–492 (2017).
   PubMed Web of Science ®Google Scholar